{"id":28703,"date":"2024-07-15T15:09:40","date_gmt":"2024-07-15T09:39:40","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=28703"},"modified":"2025-09-10T18:30:26","modified_gmt":"2025-09-10T13:00:26","slug":"fcrn-inhibitors-in-20-indications","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/fcrn-inhibitors-in-20-indications","title":{"rendered":"FcRn Inhibitors Being The Fastest Growing Class, Plans To Get Explored In 20+ Indications"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a10b248041b8\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a10b248041b8\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/fcrn-inhibitors-in-20-indications\/#Argenxs_VYVGART_the_first_mover_takes_the_stage\" >Argenx&#8217;s VYVGART, the first mover takes the stage<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/fcrn-inhibitors-in-20-indications\/#Physicians_prefer_RYSTIGGO_2nd_FcRn_for_MuSK_gMG\" >Physicians prefer RYSTIGGO (2nd FcRn) for MuSK+ gMG<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/fcrn-inhibitors-in-20-indications\/#Multiple_target_indications_increasing_the_highly_potential_addressable_market_for_FcRn_inhibitors\" >Multiple target indications, increasing the highly potential addressable market for FcRn inhibitors<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/fcrn-inhibitors-in-20-indications\/#JnJs_Nipocalimab_Next_market_entrant\" >JnJ\u2019s Nipocalimab: Next market entrant<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/fcrn-inhibitors-in-20-indications\/#Vyvgarts_reign_secure_as_Immunovant_shifts_focus\" >Vyvgart&#8217;s reign secure as Immunovant shifts focus&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/fcrn-inhibitors-in-20-indications\/#What_do_the_physicians_believe_and_practice\" >What do the physicians believe and practice?<\/a><\/li><\/ul><\/nav><\/div>\n\n<p><strong><em>Vyvgart enjoying strong commercial uptake whereas RYSTIGGO is preferred for MuSK+ Myasthenia gravis. What do the physicians believe?<\/em><\/strong><\/p>\n\n\n\n<p>The neonatal<strong> <\/strong>Fc receptor (FcRn) inhibitor market is heating up, with a growing cast of leading contenders such as <strong>Argenx, JnJ, and UCB pharma,<\/strong> along with a few early-stage players such as <strong>ACT-101 (Alpha Cancer Technologies)<\/strong>. The drugs with substantial evidence hold immense promise for revolutionizing the treatment of autoimmune diseases. Let&#8217;s delve into the current competitive landscape, exploring both approved and emerging players.&nbsp;Currently, <a href=\"https:\/\/www.delveinsight.com\/blog\/fcrn-inhibitors-for-autoimmune-disorders\">FcRn inhibitors<\/a> are approved in three indications including <strong>Myasthenia gravis, primary immune thrombocytopenia (ITP), <\/strong>and<strong> chronic inflammatory demyelinating polyneuropathy (CIDP)<\/strong>, spanning multiple therapy areas including, <strong>Neurology, Rheumatology, Endocrinology, Dermatology, Hematology, Renal and others.<\/strong><\/p>\n\n\n\n<p><span id=\"docs-internal-guid-255b74c7-7fff-ba7a-8b57-38dd3da73392\"><\/span><\/p>\n<div dir=\"ltr\" style=\"margin-left: 0pt;\" align=\"left\">\n<table style=\"border: none; border-collapse: collapse;\"><colgroup><col width=\"324\" \/><col width=\"306\" \/><\/colgroup>\n<tbody>\n<tr style=\"height: 0pt;\">\n<td style=\"vertical-align: middle; background-color: #4ec1e3; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\" colspan=\"2\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: center; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">FcRn inhibitors opportunity in top indications&nbsp;<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 0pt;\">\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Indication<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Prevalent Cases in the US (2023)&nbsp;<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 0pt;\">\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Myasthenia gravis<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">&tilde;130,000<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 0pt;\">\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Primary immune thrombocytopenia (ITP)<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">&tilde;66,000<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 0pt;\">\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Chronic inflammatory demyelinating polyneuropathy (CIDP)<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">&tilde;40,000<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 0pt;\">\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Sjogren&#8217;s Disease<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">&tilde;1,700,000<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 0pt;\">\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Warm Autoimmune Hemolytic Anemia (wAIHA)<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">&tilde;42,000<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 0pt;\">\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Systemic lupus erythematosus (SLE)<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">&tilde;300,000<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 0pt;\">\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Rheumatoid arthritis<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">&tilde;1,400,000<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 0pt;\">\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: italic; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Delveinsight Estimates, 2023<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">&nbsp;<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-argenx-s-vyvgart-the-first-mover-takes-the-stage\"><span class=\"ez-toc-section\" id=\"Argenxs_VYVGART_the_first_mover_takes_the_stage\"><\/span><strong>Argenx&#8217;s VYVGART, the first mover takes the stage<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>In recent years, FcRn inhibitors have emerged as a promising <a href=\"https:\/\/www.delveinsight.com\/report-store\/generalized-myasthenia-gravis-gmg-market\">treatment option for patients with generalized myasthenia gravis (gMG)<\/a>, which accounts for 80\u201385% of myasthenia gravis cases. <strong>Argenx&#8217;s VYVGART <\/strong>(Efgartigimod alfa), as the first FDA-approved FcRn inhibitor, has achieved significant commercial success, reaching blockbuster status within the first 2 years of launch, posting sales of USD 400 million in 2022 and USD 1.2 billion in 2023, with growth driven by new patient starts and penetration into earlier lines.<\/p>\n\n\n\n<p><strong>VYVGART<\/strong> achieved a milestone in December 2021, securing the first FDA approval as a FcRn inhibitor, targeting generalized myasthenia gravis in adults with an anti-acetylcholine receptor (AChR) antibody. Based on multiple physicians\u2019 perspectives, ~50% of gMG patients are currently on a novel agent, with the split being 60% on FcRn, and 40% on <a href=\"https:\/\/www.delveinsight.com\/report-store\/complement-inhibitors-c3-c5-competitive-market-forecast\">complement inhibitors<\/a>, which we believe could be vice-versa in varied scenarios.<\/p>\n\n\n\n<p>In June 2023, Argenx gained FDA approval for the subcutaneous formulation, <a href=\"https:\/\/www.delveinsight.com\/blog\/fcrn-inhibitors-for-autoimmune-disorders\"><strong>VYVGART Hytrulo<\/strong><\/a>, offering a 1,008 mg fixed dose via a single injection over 30\u201390 seconds in weekly cycles for 4 weeks. VYVGART is approved across the US, Japan, Europe, the UK, Israel, Mainland China, and Canada for gMG, while VYVGART SC is approved in the US, Europe, the UK, and Japan<strong>. <\/strong>As of May 2024, over 10,000 patients have been treated globally with both formulations.<\/p>\n\n\n\n<p>VYVGART Hytrulo is poised to be a significant revenue driver for Argenx in the near term. In March 2024, the MHLW also approved VYVGART IV for primary immune thrombocytopenia (ITP). In June 2024, the FDA approved VYVGART HYTRULO for CIDP, widening its window to another important segment of patients. While the failure of<strong> UCB\u2019s rozanolixizumab<\/strong> has eliminated the threat to VYVGART in the competitive landscape of CIDP it will be up against <strong>Takeda\u2019s<\/strong> already-approved subcutaneous immune globulin treatment <strong>HYQVIA<\/strong>.<\/p>\n\n\n\n<p>The added dosing convenience should help protect VYVGART\u2019s competitive positioning against other FcRn blockers and other approved treatment modalities for gMG, including C5 inhibitors: ULTOMIRIS and ZILUCOPLAN. Due to its compelling clinical profile, broad label, and added dosing flexibility with the approval of HYTRULO.<\/p>\n\n\n\n<p>Despite setbacks in trials for pemphigus vulgaris and ITP and discontinuation in ANCA-associated vasculitis, VYVGART posted a 6% quarter-over-quarter increase, reaching <strong>USD 398 million in Q1 2024<\/strong>. With approvals in three indications\u2014gMG, CIDP, and ITP\u2014Argenx continues to work to further expand Vyvgart\u2019s reach in gMG by broadening its addressable myasthenia gravis population to include seronegative patients, with registrational studies planned for 2024. The company is also advancing the development of a pre-filled syringe, which would enable patients to self-administer the drug.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"394\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/15150455\/Quaterly-Revenue-Uptake-of-VYVGART-Hytrulo-1024x394.png\" alt=\"Quaterly Revenue Uptake of VYVGART Hytrulo\" class=\"wp-image-28707\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/15150455\/Quaterly-Revenue-Uptake-of-VYVGART-Hytrulo-1024x394.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/15150455\/Quaterly-Revenue-Uptake-of-VYVGART-Hytrulo-300x116.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/15150455\/Quaterly-Revenue-Uptake-of-VYVGART-Hytrulo-150x58.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/15150455\/Quaterly-Revenue-Uptake-of-VYVGART-Hytrulo-768x296.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/15150455\/Quaterly-Revenue-Uptake-of-VYVGART-Hytrulo-1536x591.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/15150455\/Quaterly-Revenue-Uptake-of-VYVGART-Hytrulo-2048x788.png 2048w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/15150455\/Quaterly-Revenue-Uptake-of-VYVGART-Hytrulo-1568x604.png 1568w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Physicians_prefer_RYSTIGGO_2nd_FcRn_for_MuSK_gMG\"><\/span><strong>Physicians prefer RYSTIGGO (2<\/strong><strong><sup>nd<\/sup><\/strong><strong> FcRn) for MuSK+ gMG<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>UCB\u2019s RSYTIGGO<\/strong> (rozanolixizumab) emerged victorious in June 2023, securing the second FDA approval as a <a href=\"https:\/\/www.delveinsight.com\/report-store\/fcrn-inhibitor-competitive-landscape-and-market-forecast\">FcRn inhibitor for gMG<\/a>. RYSTIGGO is the first approved therapy to treat the two main subsets of gMG\u2014those positive for the anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibodies. This dual mechanism may be a threat to argenx\u2019s VYVGART, which only targets AChR gMG.<\/p>\n\n\n\n<p>\u201c<em>No two people living with gMG experience the disease in the same way, so we can\u2019t take a \u2018one size fits all\u2019 approach to disease management<\/em>,\u201d said Iris Loew-Friedrich, Executive Vice-President and Chief Medical Officer at UCB.<\/p>\n\n\n\n<p>UCB launched RYSTIGGO in the US in July 2023 and at the end of 2023 in Japan. UCB kept the price at USD 6,050 per vial with varying dosages based on the patient&#8217;s weight and the severity of symptoms. Whereas the WAC price of VYVGART HYTRULO fixed dose is <strong>~USD 15,700 USD per vial<\/strong>. RYSTIGGO is advised to be administered as a subcutaneous infusion with an infusion pump at a maximum rate of 20 mL per hour, once a week for 6 weeks. On the other hand, VYVGART Hytrulo is given as a subcutaneous injection over about 30 to 90 seconds, following a cycle of once-weekly injections for 4 weeks, offering greater convenience.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"353\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/15150550\/FcRn-Inhbitors-with-Number-of-Targeted-Indications-Approved-and-Emerging-1024x353.png\" alt=\"FcRn Inhbitors with Number of Targeted Indications (Approved and Emerging)\" class=\"wp-image-28708\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/15150550\/FcRn-Inhbitors-with-Number-of-Targeted-Indications-Approved-and-Emerging-1024x353.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/15150550\/FcRn-Inhbitors-with-Number-of-Targeted-Indications-Approved-and-Emerging-300x104.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/15150550\/FcRn-Inhbitors-with-Number-of-Targeted-Indications-Approved-and-Emerging-150x52.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/15150550\/FcRn-Inhbitors-with-Number-of-Targeted-Indications-Approved-and-Emerging-768x265.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/15150550\/FcRn-Inhbitors-with-Number-of-Targeted-Indications-Approved-and-Emerging-1536x530.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/15150550\/FcRn-Inhbitors-with-Number-of-Targeted-Indications-Approved-and-Emerging-2048x707.png 2048w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/15150550\/FcRn-Inhbitors-with-Number-of-Targeted-Indications-Approved-and-Emerging-1568x541.png 1568w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p>Immunovant has announced the development in around 23 indications, only 5 indications are in the pipeline others are in preclinical or planned.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Multiple_target_indications_increasing_the_highly_potential_addressable_market_for_FcRn_inhibitors\"><\/span><strong>Multiple target indications, increasing the highly potential addressable market for FcRn inhibitors<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>While the approved frontrunners dominate the <a href=\"https:\/\/www.delveinsight.com\/report-store\/generalized-myasthenia-gravis-gmg-market\">gMG market<\/a>, the pipeline brims with contenders for various autoimmune and neurological indications.<\/p>\n\n\n\n<p><span id=\"docs-internal-guid-271e5222-7fff-b590-cac0-0ea5d43b8499\"><\/span><\/p>\n<div dir=\"ltr\" style=\"margin-left: 0pt;\" align=\"left\">\n<table style=\"border: none; border-collapse: collapse;\"><colgroup><col width=\"156\" \/><col width=\"198\" \/><col width=\"312\" \/><\/colgroup>\n<tbody>\n<tr style=\"height: 0pt;\">\n<td style=\"vertical-align: top; background-color: #4ec1e3; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\" colspan=\"3\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: center; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">The broad scope of FcRn inhibitors<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 0pt;\">\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Drug Name<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Company Name<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Targeted Indications<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 0pt;\">\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Nipocalimab<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Johnson &amp; Johnson<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Warm Autoimmune Hemolytic Anemia, Idiopathic Inflammatory myopathy, Hemolytic disease of the fetus and newborn, Systemic lupus erythematosus, Rheumatoid arthritis, Sjogren&rsquo;s disease, Myasthenia gravis, and CIDP<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 0pt;\">\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Batoclimab and IMVT-1402<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Immunovant<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">CIDP, Myasthenia gravis, Grave&rsquo;s disease, and Thyroid eye disease and more than 20 others planned<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 0pt;\">\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">ACT-101 (Alpha Fetoprotein)<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Alpha Cancer Technologies<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Myasthenia gravis, IBD (Crohn&rsquo;s\/Colitis), Hashimoto Disease, Multiple Sclerosis, 40+ Others planning<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 0pt;\">\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">VRDN-006<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Viridian Therapeutics<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">In Preclinical &ndash; Planning CIDP, Graves disease, Myositis, Lupus Nephritis, Membranous Nephropathy, and Sjogren&rsquo;syndrome<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"JnJs_Nipocalimab_Next_market_entrant\"><\/span><strong>JnJ\u2019s Nipocalimab: Next market entrant<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Momenta Pharmaceuticals&#8217; <strong>nipocalimab<\/strong>, acquired by <strong>JnJ<\/strong> (in 2020 for USD 6.5 billion), is a rising star being evaluated in a multitude of rare diseases, including gMG. In the Phase III VIVACITY study, nipocalimab significantly reduced Myasthenia Gravis-Activities of Daily Living Scale (MG-ADL) scores in adults with gMG. Additionally, in the Phase II DAHLIAS study, nipolacimab showed significant improvement in clinESSDAI scores for Sjogren\u2019s Disease.<\/p>\n\n\n\n<p>Nipocalimab is the only anti-FcRn studied across three segments: rare autoantibody diseases (such as gMG and chronic inflammatory demyelinating polyneuropathy), maternal-fetal diseases (like hemolytic disease of the fetus and newborn), and prevalent rheumatology conditions (including rheumatoid arthritis and SjD). It has received <strong>Fast Track designation<\/strong> from the FDA for hemolytic disease of the fetus and newborn (HDFN), wAIHA, and gMG, and holds orphan drug status for multiple conditions. With potential regulatory approvals in various indications, <strong>JnJ<\/strong> envisions nipocalimab achieving blockbuster status.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Vyvgarts_reign_secure_as_Immunovant_shifts_focus\"><\/span><strong>Vyvgart&#8217;s reign secure as Immunovant shifts focus<\/strong>&nbsp;<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Immunovant\u2019s IMVT-1402<\/strong> has attracted interest due to its initial safety findings, surpassing batoclimab-Immunovant&#8217;s primary anti-FcRn in specific important criteria. Its limited impact on LDL cholesterol and serum albumin levels when taken at a 300 mg subcutaneous dose is particularly interesting. This customized decrease in IgG levels could be very important for the effectiveness of treatment in Rheumatology and Hematology, as consistent IgG reduction is crucial.<\/p>\n\n\n\n<p>From a commercial perspective, the introduction of IMVT-1402 could reshape the dynamics of the market. Despite VYGART\u2019s established presence in various indications, IMVT-1402&#8217;s different approach may give it an edge, increasing rivalry in the market.<\/p>\n\n\n\n<p><strong>Immunovant<\/strong> is prioritizing <strong>IMVT-1402<\/strong>, over <strong>batoclimab<\/strong>, keeping VYVGART&#8217;s lead secure for now. While continuing the batoclimab MG trial, Immunovant plans a potentially registrational program for IMVT-1402 in MG. A final decision will be made based on the results of the current batoclimab trial. Immunovant expects these topline results and the related decision to be by the end of this fiscal year (Q1, 2025). A clinical update for batoclimab in <a href=\"https:\/\/www.delveinsight.com\/report-store\/graves-disease-market\">Graves\u2019 disease<\/a> is expected by the end of 2024. IMVT-1402 may also replace batoclimab in a CIDP study. Immunovant aims to launch IMVT-1402 trials in 4\u20135 indications by March 2025, expanding to 10 by the following year.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_do_the_physicians_believe_and_practice\"><\/span><strong>What do the physicians believe and practice?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>The Uptake of FcRn inhibitors as a class would be higher if they were self-administered, which both Argenx and Immunovant are working towards. However, some patients prefer supervision by a healthcare provider.<\/li>\n\n\n\n<li>While several biologics are already approved for gMG, existing treatment options are somewhat limited by their black box\/REMS, high treatment burden (IV, in-office SC, or daily SC administration), and\/or cyclical dosing regimen.<\/li>\n\n\n\n<li>Vyvgart subcutaneous version has led to an increased willingness to prescribe<\/li>\n\n\n\n<li>Despite the success, a downside to FcRn inhibitors is the requirement for a more than 50-day drug holiday due to transient IgG decline &amp; infection risk, potentially leading to the rebound of autoantibodies, complement activation, &amp; symptom worsening. In an extremely optimistic view, the FcRn class could begin to resemble the TNF class for autoimmune diseases.<\/li>\n\n\n\n<li>There is no preference from Insurance companies when it comes to choosing Complement Inhibitors vs. FcRn inhibitors in patients who have already tried the standard of care<\/li>\n\n\n\n<li>Very few patients <strong>switch <\/strong>from complement inhibitors to an FcRn inhibitor<\/li>\n\n\n\n<li>In addition to <a href=\"https:\/\/www.delveinsight.com\/report-store\/fcrn-inhibitor-competitive-landscape-and-market-forecast\">FcRn antagonists<\/a> and complement inhibitors, several investigational gMG drugs have garnered physician and investor interest due to their novel mechanisms of action, such as <strong>Enspryng (satralizumab) <\/strong>and <strong>Uplizna (inebilizumab)<\/strong>.<\/li>\n<\/ul>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/fcrn-inhibitor-competitive-landscape-and-market-forecast\"><img decoding=\"async\" width=\"1024\" height=\"256\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/06124141\/FcRn-Inhibitor-Market-Outlook-1024x256.png\" alt=\"FcRn-Inhibitor-Market-Outlook\" class=\"wp-image-27897\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/06124141\/FcRn-Inhibitor-Market-Outlook-1024x256.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/06124141\/FcRn-Inhibitor-Market-Outlook-300x75.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/06124141\/FcRn-Inhibitor-Market-Outlook-150x38.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/06124141\/FcRn-Inhibitor-Market-Outlook-768x192.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/06124141\/FcRn-Inhibitor-Market-Outlook.png 1188w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n\n<p><strong>FAQs<\/strong><\/p>\n\n\n\n<div class=\"schema-faq wp-block-yoast-faq-block\"><div class=\"schema-faq-section\" id=\"faq-question-1757509127590\"><strong class=\"schema-faq-question\"><strong>Why is VYVGART considered the benchmark FcRn inhibitor?<\/strong><\/strong> <p class=\"schema-faq-answer\">Argenx\u2019s VYVGART became the first FcRn inhibitor approved in 2021 and has since achieved blockbuster status, surpassing USD 1 billion in sales by 2023. Its broad label expansion, the convenient Hytrulo formulation, and strong physician confidence make it the anchor brand in this space, despite increasing competition.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1757509128771\"><strong class=\"schema-faq-question\"><strong>What differentiates RYSTIGGO in the FcRn landscape?<\/strong><\/strong> <p class=\"schema-faq-answer\">Unlike VYVGART, which is limited to AChR-positive gMG, UCB\u2019s RYSTIGGO covers both AChR+ and MuSK+ subsets,\u00a0 a key clinical differentiator. This dual mechanism provides physicians more flexibility in tailoring treatment, especially for patients with rarer MuSK+ disease.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1757509132650\"><strong class=\"schema-faq-question\"><strong>How are FcRn inhibitors reshaping autoimmune disease treatment?<\/strong><\/strong> <p class=\"schema-faq-answer\">FcRn inhibitors are rapidly moving beyond symptom relief into disease modification. With approvals already in gMG, ITP, and CIDP, they are expanding into neurology, rheumatology, hematology, and even maternal-fetal diseases. Physicians see them as the first class with potential to mirror the broad adoption of TNF inhibitors in autoimmune care.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1757509133180\"><strong class=\"schema-faq-question\"><strong>Which FcRn pipeline drug is attracting the most attention?<\/strong><\/strong> <p class=\"schema-faq-answer\"><strong>JNJ\u2019s nipocalimab<\/strong> stands out for its breadth, spanning rare autoantibody diseases, maternal-fetal conditions, and common autoimmune disorders like Sj\u00f6gren\u2019s. With multiple Fast Track and orphan designations, <strong>it could be the next blockbuster,<\/strong> potentially rivaling VYVGART\u2019s dominance.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1757509181059\"><strong class=\"schema-faq-question\"><strong>How do payers and insurers view FcRn inhibitors compared to complement inhibitors?<\/strong><\/strong> <p class=\"schema-faq-answer\">Currently, insurers do not prioritize one class over the other for gMG patients who have failed standard therapy. However, physician behavior suggests limited switching between complement inhibitors and FcRn agents, meaning both classes may coexist rather than directly compete.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1757509181804\"><strong class=\"schema-faq-question\"><strong>What are physicians prioritizing when prescribing FcRn inhibitors?<\/strong><\/strong> <p class=\"schema-faq-answer\">Convenience and flexibility are top of mind. Many clinicians prefer subcutaneous, short-duration dosing <strong>(like Hytrulo) <\/strong>for patient compliance. Yet, some patients still prefer in-clinic supervision. Physicians also watch for safety challenges such as infection risk and IgG rebound during drug holidays.<\/p> <\/div> <\/div>\n","protected":false},"excerpt":{"rendered":"<p>Vyvgart enjoying strong commercial uptake whereas RYSTIGGO is preferred for MuSK+ Myasthenia gravis. What do the physicians believe? The neonatal Fc receptor (FcRn) inhibitor market is heating up, with a growing cast of leading contenders such as Argenx, JnJ, and UCB pharma, along with a few early-stage players such as ACT-101 (Alpha Cancer Technologies). The [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":28705,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[22084,22083,22085,18983,12945,1554,18974,22195],"industry":[17225],"therapeutic_areas":[17227],"class_list":["post-28703","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-fcrn-inhibitor","tag-fcrn-inhibitors","tag-fcrn-inhibitors-market","tag-generalized-myasthenia-gravis","tag-immune-thrombocytopenia","tag-myasthenia-gravis","tag-vyvgart","tag-vyvgart-hytrulo","industry-pharmaceutical","therapeutic_areas-immunological-and-autoimmune-disorders"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>FcRn Inhibitors to Rapidly Expand, Targeting Over 20 Conditions<\/title>\n<meta name=\"description\" content=\"The (FcRn inhibitor market is heating up, with a growing cast of leading contenders such as Argenx, JnJ, and UCB pharma.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/fcrn-inhibitors-in-20-indications\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FcRn Inhibitors to Rapidly Expand, Targeting Over 20 Conditions\" \/>\n<meta property=\"og:description\" content=\"The (FcRn inhibitor market is heating up, with a growing cast of leading contenders such as Argenx, JnJ, and UCB pharma.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/fcrn-inhibitors-in-20-indications\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-07-15T09:39:40+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-10T13:00:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/15150016\/fcrn-inhibitors-in-20-indications.png\" \/>\n\t<meta property=\"og:image:width\" content=\"466\" \/>\n\t<meta property=\"og:image:height\" content=\"284\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"9 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"FcRn Inhibitors to Rapidly Expand, Targeting Over 20 Conditions","description":"The (FcRn inhibitor market is heating up, with a growing cast of leading contenders such as Argenx, JnJ, and UCB pharma.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/fcrn-inhibitors-in-20-indications","og_locale":"en_US","og_type":"article","og_title":"FcRn Inhibitors to Rapidly Expand, Targeting Over 20 Conditions","og_description":"The (FcRn inhibitor market is heating up, with a growing cast of leading contenders such as Argenx, JnJ, and UCB pharma.","og_url":"https:\/\/www.delveinsight.com\/blog\/fcrn-inhibitors-in-20-indications","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2024-07-15T09:39:40+00:00","article_modified_time":"2025-09-10T13:00:26+00:00","og_image":[{"width":466,"height":284,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/15150016\/fcrn-inhibitors-in-20-indications.png","type":"image\/png"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"9 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":["WebPage","FAQPage"],"@id":"https:\/\/www.delveinsight.com\/blog\/fcrn-inhibitors-in-20-indications","url":"https:\/\/www.delveinsight.com\/blog\/fcrn-inhibitors-in-20-indications","name":"FcRn Inhibitors to Rapidly Expand, Targeting Over 20 Conditions","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/fcrn-inhibitors-in-20-indications#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/fcrn-inhibitors-in-20-indications#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/15150016\/fcrn-inhibitors-in-20-indications.png","datePublished":"2024-07-15T09:39:40+00:00","dateModified":"2025-09-10T13:00:26+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"The (FcRn inhibitor market is heating up, with a growing cast of leading contenders such as Argenx, JnJ, and UCB pharma.","mainEntity":[{"@id":"https:\/\/www.delveinsight.com\/blog\/fcrn-inhibitors-in-20-indications#faq-question-1757509127590"},{"@id":"https:\/\/www.delveinsight.com\/blog\/fcrn-inhibitors-in-20-indications#faq-question-1757509128771"},{"@id":"https:\/\/www.delveinsight.com\/blog\/fcrn-inhibitors-in-20-indications#faq-question-1757509132650"},{"@id":"https:\/\/www.delveinsight.com\/blog\/fcrn-inhibitors-in-20-indications#faq-question-1757509133180"},{"@id":"https:\/\/www.delveinsight.com\/blog\/fcrn-inhibitors-in-20-indications#faq-question-1757509181059"},{"@id":"https:\/\/www.delveinsight.com\/blog\/fcrn-inhibitors-in-20-indications#faq-question-1757509181804"}],"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/fcrn-inhibitors-in-20-indications"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/fcrn-inhibitors-in-20-indications#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/15150016\/fcrn-inhibitors-in-20-indications.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/15150016\/fcrn-inhibitors-in-20-indications.png","width":466,"height":284,"caption":"fcrn-inhibitors-in-20-indications"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/fcrn-inhibitors-in-20-indications#faq-question-1757509127590","position":1,"url":"https:\/\/www.delveinsight.com\/blog\/fcrn-inhibitors-in-20-indications#faq-question-1757509127590","name":"Why is VYVGART considered the benchmark FcRn inhibitor?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Argenx\u2019s VYVGART became the first FcRn inhibitor approved in 2021 and has since achieved blockbuster status, surpassing USD 1 billion in sales by 2023. Its broad label expansion, the convenient Hytrulo formulation, and strong physician confidence make it the anchor brand in this space, despite increasing competition.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/fcrn-inhibitors-in-20-indications#faq-question-1757509128771","position":2,"url":"https:\/\/www.delveinsight.com\/blog\/fcrn-inhibitors-in-20-indications#faq-question-1757509128771","name":"What differentiates RYSTIGGO in the FcRn landscape?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Unlike VYVGART, which is limited to AChR-positive gMG, UCB\u2019s RYSTIGGO covers both AChR+ and MuSK+ subsets,\u00a0 a key clinical differentiator. This dual mechanism provides physicians more flexibility in tailoring treatment, especially for patients with rarer MuSK+ disease.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/fcrn-inhibitors-in-20-indications#faq-question-1757509132650","position":3,"url":"https:\/\/www.delveinsight.com\/blog\/fcrn-inhibitors-in-20-indications#faq-question-1757509132650","name":"How are FcRn inhibitors reshaping autoimmune disease treatment?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"FcRn inhibitors are rapidly moving beyond symptom relief into disease modification. With approvals already in gMG, ITP, and CIDP, they are expanding into neurology, rheumatology, hematology, and even maternal-fetal diseases. Physicians see them as the first class with potential to mirror the broad adoption of TNF inhibitors in autoimmune care.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/fcrn-inhibitors-in-20-indications#faq-question-1757509133180","position":4,"url":"https:\/\/www.delveinsight.com\/blog\/fcrn-inhibitors-in-20-indications#faq-question-1757509133180","name":"Which FcRn pipeline drug is attracting the most attention?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"<strong>JNJ\u2019s nipocalimab<\/strong> stands out for its breadth, spanning rare autoantibody diseases, maternal-fetal conditions, and common autoimmune disorders like Sj\u00f6gren\u2019s. With multiple Fast Track and orphan designations, <strong>it could be the next blockbuster,<\/strong> potentially rivaling VYVGART\u2019s dominance.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/fcrn-inhibitors-in-20-indications#faq-question-1757509181059","position":5,"url":"https:\/\/www.delveinsight.com\/blog\/fcrn-inhibitors-in-20-indications#faq-question-1757509181059","name":"How do payers and insurers view FcRn inhibitors compared to complement inhibitors?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Currently, insurers do not prioritize one class over the other for gMG patients who have failed standard therapy. However, physician behavior suggests limited switching between complement inhibitors and FcRn agents, meaning both classes may coexist rather than directly compete.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/fcrn-inhibitors-in-20-indications#faq-question-1757509181804","position":6,"url":"https:\/\/www.delveinsight.com\/blog\/fcrn-inhibitors-in-20-indications#faq-question-1757509181804","name":"What are physicians prioritizing when prescribing FcRn inhibitors?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Convenience and flexibility are top of mind. Many clinicians prefer subcutaneous, short-duration dosing <strong>(like Hytrulo) <\/strong>for patient compliance. Yet, some patients still prefer in-clinic supervision. Physicians also watch for safety challenges such as infection risk and IgG rebound during drug holidays.","inLanguage":"en-US"},"inLanguage":"en-US"}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/15150016\/fcrn-inhibitors-in-20-indications-300x183.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">FcRn Inhibitor<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">FcRn Inhibitors<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">FcRn Inhibitors Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Generalized Myasthenia Gravis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Immune Thrombocytopenia<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">myasthenia gravis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Vyvgart<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">VYVGART Hytrulo<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">FcRn Inhibitor<\/span>","<span class=\"advgb-post-tax-term\">FcRn Inhibitors<\/span>","<span class=\"advgb-post-tax-term\">FcRn Inhibitors Market<\/span>","<span class=\"advgb-post-tax-term\">Generalized Myasthenia Gravis<\/span>","<span class=\"advgb-post-tax-term\">Immune Thrombocytopenia<\/span>","<span class=\"advgb-post-tax-term\">myasthenia gravis<\/span>","<span class=\"advgb-post-tax-term\">Vyvgart<\/span>","<span class=\"advgb-post-tax-term\">VYVGART Hytrulo<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 2 years ago","modified":"Updated 8 months ago"},"absolute_dates":{"created":"Posted on Jul 15, 2024","modified":"Updated on Sep 10, 2025"},"absolute_dates_time":{"created":"Posted on Jul 15, 2024 3:09 pm","modified":"Updated on Sep 10, 2025 6:30 pm"},"featured_img_caption":"fcrn-inhibitors-in-20-indications","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/28703","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=28703"}],"version-history":[{"count":3,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/28703\/revisions"}],"predecessor-version":[{"id":33353,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/28703\/revisions\/33353"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/28705"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=28703"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=28703"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=28703"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=28703"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=28703"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}